Literature DB >> 18497454

Contribution of fasting and postprandial hyperglycemia to hemoglobin A1c in insulin-treated Japanese diabetic patients.

Hiroyuki Shimizu1, Yutaka Uehara, Shuichi Okada, Masatomo Mori.   

Abstract

The contribution of fasting and postprandial glucose to hemoglobin A(1c) (HbA(1c)) levels was evaluated in insulin-treated patients. In 57 insulin-treated, diabetic out-patients, fasting glucose (before breakfast (B-FG), lunch (L-FG) and dinner (D-FG)) and postprandial glucose (B-PPG, L-PPG and D-PPG) levels were determined by the patients themselves at home using glucose self-monitoring apparatus over the course of one week. The correlation between HbA(1c) levels and self monitored blood glucose levels were calculated. In the conventionally treated group, there was a significant correlation between HbA(1c) and fasting glucose (FG) levels only before lunch, but at 2 hr after (PPG) all meals. In the intensively treated group, a significant correlation between HbA(1c) levels and FG levels was found before lunch and at 2 hr after breakfast and dinner. In all subjects, only FG levels before lunch correlated significantly with HbA(1c) levels, although PPG levels were significantly correlated with HbA(1c) at all points. The correlation was highest with PPG after breakfast and dinner. The sum of all FG, PPG and FG + PPG levels was significantly correlated with HbA(1c) levels. Postprandial hyperglycemia after breakfast and dinner should be regarded as most important for improving HbA(1c) levels in insulin treated diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18497454     DOI: 10.1507/endocrj.k07e-142

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  7 in total

1.  Fast-acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart.

Authors:  Masanari Shiramoto; Tomoyuki Nishida; Ann Kathrine Hansen; Hanne Haahr
Journal:  J Diabetes Investig       Date:  2017-07-07       Impact factor: 4.232

2.  Relationship of glycated hemoglobin, and fasting and postprandial hyperglycemia in type 2 diabetes mellitus patients in Malaysia.

Authors:  Lee Ling Lim; Alan Jm Brnabic; Siew Pheng Chan; Luqman Ibrahim; Sharmila Sunita Paramasivam; Jeyakantha Ratnasingam; Shireene Ratna Vethakkan; Alexander Tong Boon Tan
Journal:  J Diabetes Investig       Date:  2016-12-27       Impact factor: 4.232

3.  Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus.

Authors:  Kun Ho Yoon; Elise Hardy; Jenny Han
Journal:  Diabetes Metab J       Date:  2016-12-26       Impact factor: 5.376

4.  Blood glucose profiles in East Asian and Caucasian injection-naive patients with type 2 diabetes inadequately controlled on oral medication: a pooled analysis.

Authors:  Xiao Mei Zhang; Peng Fei Li; Jia Ning Hou; Li Nong Ji
Journal:  Diabetes Metab Res Rev       Date:  2018-10-02       Impact factor: 4.876

5.  Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.

Authors:  J A Davidson; C Desouza; V Fonseca; J P Frias; L Van Gaal; F Giorgino; J Chao; T A Dex; M Roberts; A Saremi; L A Leiter
Journal:  Diabet Med       Date:  2019-11-26       Impact factor: 4.359

6.  Contributions of Fasting and Postprandial Glucose Concentrations to Haemoglobin A1c in Drug-Naïve Mal-Glucose Metabolism in Chinese Population Using Continuous Glucose Monitoring System.

Authors:  Rengna Yan; Yun Hu; Fengfei Li; Lanlan Jiang; Xiaohua Xu; Jie Wang; Ying Zhang; Lei Ye; Kok Onn Lee; Xiaofei Su; Jianhua Ma
Journal:  Int J Endocrinol       Date:  2019-12-01       Impact factor: 3.257

7.  Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.

Authors:  Jonathan E Shaw; Baptist Gallwitz; Jenny Han; Elise Hardy; Guntram Schernthaner
Journal:  Diabetes Obes Metab       Date:  2017-07-25       Impact factor: 6.577

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.